The latest price target for Astria Therapeutics (NASDAQ:ATXS) was reported by Cantor Fitzgerald on November 12, 2025. The analyst firm set a price target for $0.00 expecting ATXS to fall to within 12 months (a possible -100.00% downside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Astria Therapeutics (NASDAQ:ATXS) was provided by Cantor Fitzgerald, and Astria Therapeutics downgraded their neutral rating.

There is no last upgrade for Astria Therapeutics

The last downgrade for Astria Therapeutics Inc happened on November 12, 2025 when Cantor Fitzgerald changed their price target from N/A to N/A for Astria Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Astria Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Astria Therapeutics was filed on November 12, 2025 so you should expect the next rating to be made available sometime around November 12, 2026.

While ratings are subjective and will change, the latest Astria Therapeutics (ATXS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Astria Therapeutics (ATXS) is trading at is $12.92, which is out of the analyst’s predicted range.